Biomarin Pharmaceutical INC (BMRN) Shareholder Highline Capital Management LLC Has Increased Position by $4.28 Million as Market Valuation Rose

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) LogoInvestors sentiment increased to 1.21 in Q2 2018. Its up 0.25, from 0.96 in 2018Q1. It is positive, as 30 investors sold BMRN shares while 118 reduced holdings. 57 funds opened positions while 122 raised stakes. 177.65 million shares or 1.83% more from 174.46 million shares in 2018Q1 were reported. Plante Moran Fincl Advisors Lc reported 25 shares stake. Gamco Investors Incorporated Et Al has 2,300 shares. Assetmark Incorporated reported 145 shares. Temasek (Private) Limited reported 1.72% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Jnba Advsr reported 140 shares or 0% of all its holdings. Ubs Asset Management Americas Inc holds 0% or 1.18M shares in its portfolio. The New York-based Allen Invest Management Ltd has invested 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Alliancebernstein Lp has 108,368 shares. 3.80M were accumulated by State Street. Profund Advisors stated it has 0.25% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Renaissance Techs Limited Liability has 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 128,571 shares. Stifel has invested 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Catawba Mgmt Va has invested 0.07% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Wealthtrust has invested 0.02% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Tarbox Family Office has invested 0.04% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Since June 11, 2018, it had 0 buys, and 22 selling transactions for $12.94 million activity. BIENAIME JEAN JACQUES also sold $149,040 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares. 7,500 shares were sold by LEWIS ALAN, worth $743,327. FUCHS HENRY J sold $2.49M worth of stock. $98,985 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares were sold by Ajer Jeffrey Robert. Davis George Eric also sold $220,386 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Friday, September 14. 3,145 shares were sold by Mueller Brian, worth $312,928 on Friday, June 22.

Highline Capital Management Llc increased its stake in Biomarin Pharmaceutical Inc (BMRN) by 3.58% based on its latest 2018Q2 regulatory filing with the SEC. Highline Capital Management Llc bought 45,550 shares as the company’s stock rose 10.80% with the market. The hedge fund held 1.32 million shares of the major pharmaceuticals company at the end of 2018Q2, valued at $124.29 million, up from 1.27M at the end of the previous reported quarter. Highline Capital Management Llc who had been investing in Biomarin Pharmaceutical Inc for a number of months, seems to be bullish on the $16.51 billion market cap company. The stock decreased 2.97% or $2.84 during the last trading session, reaching $92.7. About 713,773 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 7.26% since December 8, 2017 and is uptrending. It has underperformed by 8.36% the S&P500.

Highline Capital Management Llc, which manages about $3.04B and $2.99B US Long portfolio, decreased its stake in Hilton Grand Vacations Inc by 1.41M shares to 513,560 shares, valued at $17.82 million in 2018Q2, according to the filing. It also reduced its holding in Amazon Com Inc (NASDAQ:AMZN) by 20,100 shares in the quarter, leaving it with 71,309 shares, and cut its stake in Liberty Global Plc (NASDAQ:LBTYK).

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Seekingalpha.com which released: “Sangamo Q3 2018 First Look: Dancing With Data – Seeking Alpha” on November 12, 2018, also Nasdaq.com with their article: “Analysis: Positioning to Benefit within BioMarin Pharmaceutical, Ritchie Bros. Auctioneers, ADTRAN, Aspen Technology, AMC Entertainment, and Halliburton — Research Highlights Growth, Revenue, and Consolidated Results – Nasdaq” published on December 07, 2018, Nasdaq.com published: “BioMarin Pharmaceutical (BMRN) Down 3.1% Since Earnings Report: Can It Rebound? – Nasdaq” on March 26, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Nasdaq.com and their article: “BioMarin (BMRN) to Report Q2 Earnings: What’s in the Cards? – Nasdaq” published on July 30, 2018 as well as Nasdaq.com‘s news article titled: “Nasdaq 100 Movers: XRAY, BMRN – Nasdaq” with publication date: August 07, 2018.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 9 analysts covering BioMarin (NASDAQ:BMRN), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. BioMarin had 12 analyst reports since June 15, 2018 according to SRatingsIntel. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Wedbush on Friday, June 15. As per Friday, August 3, the company rating was maintained by Stifel Nicolaus. Citigroup maintained the stock with “Buy” rating in Thursday, August 9 report. The rating was maintained by Wedbush on Monday, August 6 with “Outperform”. The firm has “Outperform” rating given on Monday, July 9 by Credit Suisse. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Buy” rating given on Tuesday, October 23 by Canaccord Genuity. On Friday, October 26 the stock rating was maintained by Raymond James with “Outperform”. As per Wednesday, November 28, the company rating was maintained by Cantor Fitzgerald. Morgan Stanley maintained it with “Overweight” rating and $115 target in Friday, August 3 report. The company was maintained on Monday, August 6 by Barclays Capital.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.